Close Menu

NEW YORK ─ The US Food and Drug Administration on Thursday granted Emergency Use Authorization to life science reagent company Zymo Research for its Quick SARS-CoV-2 rRT-PCR Kit for the detection of SARS-CoV-2 coronavirus.

The molecular kit, developed by the Irvine, California-based firm, has been authorized as a laboratory test for the detection of nucleic acid from SARS-CoV-2 in upper and lower respiratory specimens from patients suspected of COVID-19, the agency said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.